NCI Community Oncology Research Program - Protocol Summary
DCP-001 -"Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)"
The summary below serves as a brief review of the treatment plan and eligibility for the protocol.
This summary is not intended to be used in place of the full eligibility & treatment information in the protocol.
Please contact NCORP-KC for complete protocol information.
Cancer Control Clinical Trial
CANCER TYPE: Any Site
RESEARCH BASE: NCI
HIPPA FORM: DOWNLOAD HIPPA FORM
Consent Form: VIEW CONSENT FORM
UPDATED ON 03/05/2019 (21:47:21)
Additional Consent Form: VIEW CONSENT FORM 2
UPDATED ON 03/05/2019 (22:01:53)
Additional Consent Form: VIEW CONSENT FORM 3
Collect expanded demographic and clinical data (e.g., socio economic situation, co-morbidities, method of diagnosis) across the NCORP network to help identify and best characterize patients that are screened but not enrolled and for patients that participate in NCI trials, to understand how these variables may impact outcomes.
All potential study participants must be asked to participate in the screening tool study at the time they are screened for a DCP-001 eligible trial. All eligible trials are noted on our website.
Patients can be registered to DCP-001 once eligibility for and enrollment status to the trial for which the patient is being screened has been determined.
Patients may still be registered to DCP-001, even if they have been deemed ineligible for the cancer control or treatment study.
Patients can be registered to DCP-001 up to 4 weeks after eligibility for and enrollment status to the trial for which the patient is being screened for has been determined.
Participants may be screened for more than one trial; however, The DCP-001 informed consent document only needs to be signed once.
The questionnaire may be accessed under the link for Consent Form 2 above.
The patient script and talking points may be accessed under the link for Consent Form 3 above.
- All patients (pediatric and adults) screened for selected NCORP trials supported by the Division of Cancer Prevention (DCP) and treatment trials supported by CTEP within the NCTN. Only NCORP sites will participate in DCP-001.These trials include symptom and toxicity management, prevention, screening, post-treatment surveillance, comparative effectiveness, late phase treatment trials and select phase II treatment trials. Cancer care delivery clinical trials will be included if the primary aim focuses on a patient intervention. A screened patient will be defined as one meeting the following minimum eligibility criteria per the protocol being screened for:
- Cancer diagnosis including stage and histology or pre-malignancy (not applicable to prevention, screening or post-treatment surveillance trials)
- Age range specified in the protocol for which the patient is being screened
- Indication for the study intervention (e.g., symptom, toxicity)
- A legally authorized representative may consent for a participant with impaired decision making.